In summary, GPP could ameliorate NASH possibly mediated via the modulation of gut microbiota and the TLR2/NLRP3 signaling pathway, indicating that GPP could be tested as a prebiotic agent in the prevention of NASH. The gene discussed is TLR2; the disease is metabolic dysfunction-associated steatohepatitis.